Analysts have been eager to weigh in on the Healthcare sector with new ratings on LivaNova (LIVN – Research Report), Immutep (IMMP – Research Report) and Nurix Therapeutics (NRIX – Research Report).
LivaNova (LIVN)
In a report issued on November 2, Anthony Petrone from Mizuho Securities maintained a Hold rating on LivaNova, with a price target of $56.00. The company’s shares closed last Friday at $49.96.
According to TipRanks.com, Petrone is a 1-star analyst with an average return of
LivaNova has an analyst consensus of Hold, with a price target consensus of $56.25, which is a 13.7% upside from current levels. In a report issued on November 1, Robert W. Baird also assigned a Hold rating to the stock with a $55.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Immutep (IMMP)
Robert W. Baird analyst Joel Beatty reiterated a Buy rating on Immutep on November 1 and set a price target of $7.00. The company’s shares closed last Friday at $1.90, close to its 52-week low of $1.50.
According to TipRanks.com, Beatty is a 2-star analyst with an average return of
Currently, the analyst consensus on Immutep is a Moderate Buy with an average price target of $8.50, implying a 347.4% upside from current levels. In a report issued on October 23, Maxim Group also maintained a Buy rating on the stock with a $10.00 price target.
Nurix Therapeutics (NRIX)
In a report issued on November 2, Christopher Liu from Leerink Partners maintained a Buy rating on Nurix Therapeutics. The company’s shares closed last Friday at $6.46.
According to TipRanks.com, Liu is ranked 0 out of 5 stars with an average return of
Nurix Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $28.33, which is a 393.6% upside from current levels. In a report issued on November 1, RBC Capital also assigned a Buy rating to the stock with a $24.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LIVN:
